Toggle

A drug, ZE46-0134, to treat acute myeloid leukemia (AML) with FLT3 mutation (FLT3+) or spliceosome mutation

Print

18 and older

Phase 1

12 Locations

NCT06366789

Clinical Trial Goal


To find out:
  • The highest dose of ZE46-0134 that's safe to give
  • If ZE46-0134 is safe and works well to treat FLT3+ AML or AML with spliceosome mutation

You may be able to join this trial if you:


  • Are 18 years old or older
  • Have AML
  • Have cancer cells with any of the following mutations. Your doctor can tell you this:
    • FLT3
    • SF3B1
    • SRSF2
    • U2AF1
    • ZRSR2
  • Do not have acute promyelocytic leukemia 
  • Agree to have other standard tests done to see if you can be in the clinical trial 

Trial Details


ZE46-0134 is a small molecule inhibitor that blocks FLT3 and IRAK4 in certain cells. 

You’ll get treatment in cycles that last 1 month. In each cycle you'll get:
  • ZE46-0134 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been

You may continue treatment for 2 years. You'll have biopsies to see how well the treatment is working.

The Food and Drug Administration (FDA) has not yet approved ZE46-0134. 

Contacts


Kate Dokukina, PhD, MD, +38269728309, kdokukina@eileanther.com

Locations

University of California, Los AngelesRECRUITING

Los Angeles, California
Schiller

University of California, San FranciscoRECRUITING

San Francisco, California
Olin

Emory UniversityRECRUITING

Atlanta, Georgia
Blum

The University of ChicagoRECRUITING

Chicago, Illinois
Stock

University of KansasRECRUITING

Lawrence, Kansas
Lin

University of MarylandRECRUITING

College Park, Maryland
Baer

Memorial Sloan Kettering Cancer CenterRECRUITING

New York, New York
Stein

University of North CarolinaRECRUITING

Chapel Hill, North Carolina
Zeidner

The Ohio State UniversityRECRUITING

Columbus, Ohio
Handa

University of CincinnatiRECRUITING

Cincinnati, Ohio
Curran

Oregon Health & Science UniversityRECRUITING

Portland, Oregon
Swords

The University of Texas Southwestern Medical CenterRECRUITING

Dallas, Texas
Madanat

ClinicalTrials.gov record


NCT06366789. First posted on 4/16/24

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org